SCHEMBL14413902

SCHEMBL14413902

COC(=O)c1cc(F)c([N+](=O)[O-])cc1N=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ FLT1 P17948 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.40
▸ ITGB1 P05556 1/20 0.38
▸ ITGA5 P08648 1/20 0.38
▸ VCAM1 P19320 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KMT2A Q03164 4/20 0.37
▸ MAPT P10636 3/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MEN1 O00255 3/20 0.36
▸ ESPL1 Q14674 1/20 0.36
▸ WDR5 P61964 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5166036 0.85 PDGFRB (0.40) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL32659715 0.85 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1560111 0.83 PDGFRB (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL14413910 0.83 HTT (0.44) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL13558990 0.83 PDGFRB (0.38) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL12021201 0.81 PDGFRB (0.52) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL14008526 0.81 PDGFRB (0.58) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2247382 0.80 PDGFRB (0.50) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL12037805 0.80 PDGFRB (0.42) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL23577770 0.79 PDGFRB (0.44) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208018-A1 Quinazoline Derivatives NOVARTIS AG (CH) 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208018-A1 Quinazoline Derivatives CYP3A5, CYP3A7, CYP3A4 PDGFRB 2395/4885FGFR1 3327/4885PDGFRA 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback